Q-Pharm
Brisbane, Queensland, 4006, Australia
NCT Number: NCT01281774
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of CSL112 in healthy volunteers after multiple infusions.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Brisbane, Queensland, 4006, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
reconstituted high density lipoprotein
Normal saline (0.9%)
Time frame: Up to 6 days after each infusion
Time frame: up to 24 hours after each infusion
Time frame: up to 6 days after each infusion
Time frame: up to 7 days after each infusion
CSL Limited
Industry
An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02206178
Healthy
Clermont-Ferrand, France
View Trial DetailsNCT07534020
Healthy
Addison, Illinois, United States
View Trial DetailsNCT07724015
Healthy
Jaén, Spain
View Trial DetailsNCT07404254
Beverage Intake, Caffeine
San Francisco, California, United States
View Trial Details